| Peer-Reviewed

Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome

Received: 20 October 2021     Accepted: 8 November 2021     Published: 17 November 2021
Views:       Downloads:
Abstract

Background: The use of the well-established markers of the Hemolysis, Elevated Liver enzymes and Low Platelet (HELLP) syndrome is very limited in the resource-poor settings of the developing populations. This study aimed to compare the readily available but invalidated biochemical markers with the well-established markers of HELLP syndrome. Methods: This was a retrospective cross-sectional study conducted among women diagnosed with HELLP syndrome in the University of Port Harcourt Teaching Hospital (UPTH) from 2011 to 2020. Data of each eligible case was acquired from the laboratory and medical records using a well-structured template and analyzed by standardized protocols. Results: A total of 230 cases of HELLP syndrome was identified; 200 complete HELLP (cHELLP) and 30 partial HELLP (pHELLP) variants. The cHELLP variants presented at an older age, higher gestational age, and had higher plasma bilirubin (PB), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) but lower albumin concentration compared to those with pHELLP variant (p<0.05). With worsening severity, there was an increasing trend of plasma creatinine and UA but a decreasing trend of albumin among the cHELLP variants (p<0.05). UA level exhibited the strongest positive correlation with PB, LDH, aspartate, and alanine aminotransferases and maintained the strongest negative correlation with platelet count among those with cHELLP variants (p<0.05). At a cut-off value of 1.5 mmol/L, plasma UA (AUC:0.968; 95%CI:0.913-1.000;p<0.001) level had the most robust ROC values compared to those of plasma creatinine and albumin among the cHELLP variants. Conclusion: From the foregoing, plasma UA should be considered as an adjunct marker of cHELLP syndrome. However, further studies are highly recommended to evaluate conclusions from this study.

Published in Journal of Gynecology and Obstetrics (Volume 9, Issue 6)
DOI 10.11648/j.jgo.20210906.16
Page(s) 217-223
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

HELLP, Complete HELLP, Partial HELLP

References
[1] Pritchard JA, Weisman R, Jr, Ratnoff OD, et al. Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. N Engl J Med. 1954; 250: 89 – 98.
[2] Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol. 2005; 193: 859.
[3] Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome) Am J Obstet Gynecol. 1993; 169:1000 – 6.
[4] Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004; 103: 981 – 91.
[5] Baxter JK, Weinstein L. HELLP syndrome: the state of the art. Obstet Gynecol Surv. 2004; 59: 838 – 45.
[6] Deruelle P, Coudoux E, Ego A, et al. Risk factors for post-partum complications occurring after preeclampsia and HELLP syndrome. A study in 453 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol. 2006; 125: 59–65.
[7] Raval DS, Co S, Reid MA, et al. Maternal and neonatal outcome of pregnancies complicated with maternal HELLP syndrome. J Perinatol. 1997; 17: 266 – 9.
[8] Isler CM, Rinehart BK, Terrone DA, et al. Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol. 1999; 181: 924 – 8.
[9] Curtin WM, Weinstein L. A review of HELLP syndrome. J Perinatol. 1999; 19: 138 – 43.
[10] Makinde ON, Adegoke OA, Adediran IA, et al. HELLP syndrome: the experience at Ile-Ife, Nigeria. J Obstet Gynaecol. 2009; 29 (3): 195-9.
[11] Onuh SO, Aisien AO. Maternal and fetal outcome in eclamptic patients in Benin City, Nigeria. J Obstet Gynaecol. 2004; 24 (7): 765-8.
[12] Tessema GA, Tekeste A, Ayele TA. Preeclampsia and associated factors among pregnant women attending antenatal care in Dessie referral hospital, Northeast Ethiopia: a hospital-based study. BMC Pregnancy Childbirth. 2015; 15: 73. doi: 10.1186/s12884-015-0502-7.
[13] Lisonkova S, Bone JN, Muraca GM, Razaz N, Wang LQ, Sabr Y, et al. Incidence and risk factors for severe preeclampsia, hemolysis, elevated liver enzymes, and low platelet count syndrome, and eclampsia at preterm and term gestation: a population-based study. Am J Obstet Gynecol. 2021. Doi: http://doi.org/10.1016/j.ajog.2021.04.261
[14] Tyas BD, Lestari P, Aldika Akbar MI. Maternal Perinatal Outcomes Related to Advanced Maternal Age in Preeclampsia Pregnant Women. J Family Reprod Health. 2019; 13 (4): 191-200.
[15] Gong L, Zhao H, Cui Y, Li X. Transcriptome analysis of placentae reveals HELLP syndrome exhibits a greater extent of placental metabolic dysfunction than preeclampsia. Hypertens Pregnancy. 202; 40 (2): 134-43. doi: 10.1080/10641955.2021.1908348.
[16] Wallace K, Harris S, Addison A, Bean C. HELLP Syndrome: Pathophysiology and Current Therapies. Curr Pharm Biotechnol. 2018; 19 (10): 816-26.
[17] Ye W, Shu H, Yu Y, Li H, Chen L, Liu J, et al. Acute kidney injury in patients with HELLP syndrome. Nephrology. 2019; 51: 1199 – 206
[18] Asghamia M, Mirblouk F, Kazemi S, Pourmarzi D, Keivani MM, Heirati SFD. Maternal serum uric acid and maternal and neonatal complications in preeclamptic women: A cross-sectional study. Int J Reprod Biomed. 2017; 15(9): 583 – 588.
[19] Bellos I, Pergialiotis V, Loutradis D, Daskalakis G. The prognostic role of serum uric acid levels in preeclampsia: A meta-analysis. J Clin Hypertens. 2020; 22: 826 – 34.
[20] Gedik E, Yucei N, Salin T, Koca E, Colak YZ, Togal T. Hemolysis, elevated liver enzymes, and low platelet syndrome: outcomes for patients admitted to intensive care at a tertiary referral hospital. Hypertens Pregnancy. 2017; 36 (1): 21-29.
[21] Chen H, Tao F, Fang X, Wang X. Association of hypoproteinemia in preeclampsia with maternal and perinatal outcomes: A retrospective analysis of high-risk women. J Res Med Sci. 2016; 21; 98. Doi:10.4103/1735-1995.193170
[22] Seong WJ, Chong GO, Hong DG, Lee YS, Cho YL, Cheun SS, et al. Clinical significance of serum albumin levels in pregnancy-related hypertension. J Obstet Gynecol Res. 2010; 36 (6): 1165 – 72.
[23] Duan Z, Li C, Leung WT, Wu J, Wang M, Ying C, Wang L. Alterations of several serum parameters are Associated with preeclampsia and may be potential markers for the assessment of PE severity. Dis Markers. 2020; 2020: 7815214. doi: 10.1155/2020/7815214.
Cite This Article
  • APA Style

    Kinikanwo Green, Collins Amadi. (2021). Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. Journal of Gynecology and Obstetrics, 9(6), 217-223. https://doi.org/10.11648/j.jgo.20210906.16

    Copy | Download

    ACS Style

    Kinikanwo Green; Collins Amadi. Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. J. Gynecol. Obstet. 2021, 9(6), 217-223. doi: 10.11648/j.jgo.20210906.16

    Copy | Download

    AMA Style

    Kinikanwo Green, Collins Amadi. Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome. J Gynecol Obstet. 2021;9(6):217-223. doi: 10.11648/j.jgo.20210906.16

    Copy | Download

  • @article{10.11648/j.jgo.20210906.16,
      author = {Kinikanwo Green and Collins Amadi},
      title = {Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome},
      journal = {Journal of Gynecology and Obstetrics},
      volume = {9},
      number = {6},
      pages = {217-223},
      doi = {10.11648/j.jgo.20210906.16},
      url = {https://doi.org/10.11648/j.jgo.20210906.16},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20210906.16},
      abstract = {Background: The use of the well-established markers of the Hemolysis, Elevated Liver enzymes and Low Platelet (HELLP) syndrome is very limited in the resource-poor settings of the developing populations. This study aimed to compare the readily available but invalidated biochemical markers with the well-established markers of HELLP syndrome. Methods: This was a retrospective cross-sectional study conducted among women diagnosed with HELLP syndrome in the University of Port Harcourt Teaching Hospital (UPTH) from 2011 to 2020. Data of each eligible case was acquired from the laboratory and medical records using a well-structured template and analyzed by standardized protocols. Results: A total of 230 cases of HELLP syndrome was identified; 200 complete HELLP (cHELLP) and 30 partial HELLP (pHELLP) variants. The cHELLP variants presented at an older age, higher gestational age, and had higher plasma bilirubin (PB), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) but lower albumin concentration compared to those with pHELLP variant (pConclusion: From the foregoing, plasma UA should be considered as an adjunct marker of cHELLP syndrome. However, further studies are highly recommended to evaluate conclusions from this study.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Comparative Analysis Between Invalidated Biochemical Markers and the Well-established Markers of HELLP Syndrome
    AU  - Kinikanwo Green
    AU  - Collins Amadi
    Y1  - 2021/11/17
    PY  - 2021
    N1  - https://doi.org/10.11648/j.jgo.20210906.16
    DO  - 10.11648/j.jgo.20210906.16
    T2  - Journal of Gynecology and Obstetrics
    JF  - Journal of Gynecology and Obstetrics
    JO  - Journal of Gynecology and Obstetrics
    SP  - 217
    EP  - 223
    PB  - Science Publishing Group
    SN  - 2376-7820
    UR  - https://doi.org/10.11648/j.jgo.20210906.16
    AB  - Background: The use of the well-established markers of the Hemolysis, Elevated Liver enzymes and Low Platelet (HELLP) syndrome is very limited in the resource-poor settings of the developing populations. This study aimed to compare the readily available but invalidated biochemical markers with the well-established markers of HELLP syndrome. Methods: This was a retrospective cross-sectional study conducted among women diagnosed with HELLP syndrome in the University of Port Harcourt Teaching Hospital (UPTH) from 2011 to 2020. Data of each eligible case was acquired from the laboratory and medical records using a well-structured template and analyzed by standardized protocols. Results: A total of 230 cases of HELLP syndrome was identified; 200 complete HELLP (cHELLP) and 30 partial HELLP (pHELLP) variants. The cHELLP variants presented at an older age, higher gestational age, and had higher plasma bilirubin (PB), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) but lower albumin concentration compared to those with pHELLP variant (pConclusion: From the foregoing, plasma UA should be considered as an adjunct marker of cHELLP syndrome. However, further studies are highly recommended to evaluate conclusions from this study.
    VL  - 9
    IS  - 6
    ER  - 

    Copy | Download

Author Information
  • Department of Obstetrics and Gynecology, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria

  • Department of Chemical Pathology, Rivers State University Teaching Hospital, Port Harcourt, Nigeria

  • Sections